作者
Jatin Patel, Damon Bass, Albertus Beishuizen, Xavier Bocca Ruiz, Hatem Boughanmi, Anthony Cahn, Hugo Colombo, Gerard J Criner, Katherine Davy, Javier de-Miguel-Díez, Pablo A Doreski, Sofia Fernandes, Bruno François, Anubha Gupta, Kate Hanrott, Timothy Hatlen, Dave Inman, John D Isaacs, Emily Jarvis, Natalia Kostina, Tatiana Kropotina, Jean-Claude Lacherade, Divya Lakshminarayanan, Pedro Martinez-Ayala, Charlene McEvoy, Ferhat Meziani, Mehran Monchi, Sumanta Mukherjee, Rosana Muñoz-Bermúdez, Jessica Neisen, Ciara O'Shea, Gaëtan Plantefeve, Lorrie Schifano, Lee E Schwab, Zainab Shahid, Michinori Shirano, Julia E Smith, Eduardo Sprinz, Charlotte Summers, Nicolas Terzi, Mark A Tidswell, Yuliya Trefilova, Russell Williamson, Duncan Wyncoll, Mark Layton
发表日期
2023/2/1
期刊
European Respiratory Journal
卷号
61
期号
2
出版商
European Respiratory Society
简介
Background
Granulocyte–macrophage colony-stimulating factor (GM-CSF) and dysregulated myeloid cell responses are implicated in the pathophysiology and severity of COVID-19.
Methods
In this randomised, sequential, multicentre, placebo-controlled, double-blind study, adults aged 18–79 years (Part 1) or ≥70 years (Part 2) with severe COVID-19, respiratory failure and systemic inflammation (elevated C-reactive protein/ferritin) received a single intravenous infusion of otilimab 90 mg (human anti-GM-CSF monoclonal antibody) plus standard care (NCT04376684). The primary outcome was the proportion of patients alive and free of respiratory failure at Day 28.
Results
In Part 1 (n=806 randomised 1:1 otilimab:placebo), 71% of otilimab-treated patients were alive and free of respiratory failure at Day 28 versus 67% who received placebo; the model-adjusted difference of 5.3% was not statistically significant (95 …
学术搜索中的文章
J Patel, D Bass, A Beishuizen, XB Ruiz, H Boughanmi… - European Respiratory Journal, 2023